Amphastar pharmaceuticals reports financial results for the three months ended june 30, 2025

- reports net revenues of $174.4 million for the three months ended june 30, 2025 - gaap net income of $31.0 million, or $0.64 per share, for the second quarter - adjusted non-gaap net income of $40.9 million, or $0.85 per share, for the second quarter - company to hold a conference call today at 2:00 p.m. pacific time rancho cucamonga, ca / access newswire / august 7, 2025 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended june 30, 2025.
AMPH Ratings Summary
AMPH Quant Ranking